Regulus Therap (RGLS) Misses Q2 EPS by 10c

Regulus Therap (NASDAQ: RGLS) reported Q2 EPS of ($0.29), $0.10 worse than the analyst estimate of ($0.19). Revenue for the quarter came in at $736 thousand versus the consensus estimate of $3.19 million.

For earnings history and earnings-related data on Regulus Therap (RGLS) click here.

You May Also Be Interested In

• Nvidia pitches Vera CPU to Chinese clients with August delivery target
• Medtronic completes $550 million Scientia Vascular acquisition
• Restoration Hardware (RH) PT Raised to $130 at Stifel After Q1 Earnings